Sahoo Manoj K, Biswas Harshita, Singh Vinita
Department of Psychiatry, Tata Main Hospital, Jamshedpur, Jharkhand, India.
Department of Obstetrics and Gynaecology, Tata Main Hospital, Jamshedpur, Jharkhand, India.
J Family Med Prim Care. 2022 Jan;11(1):350-352. doi: 10.4103/jfmpc.jfmpc_310_21. Epub 2022 Jan 31.
Women with schizophrenia have a high risk for symptom exacerbation or relapse during pregnancy and thereafter. Relapses are more frequent when antipsychotics are discontinued. Continuation of antipsychotic during pregnancy has become common and olanzapine is commonly prescribed antipsychotic. It is very important to know the safety profile of olanzapine in Indian settings. Aim of our paper is to report two cases of olanzapine use pregnancy, discuss its safety profile, and adverse effects on mother and foetus. In both of our cases, olanzapine was continued throughout pregnancy and the patients remain clinically stable as per psychiatric symptoms. In case 1 whole antinatal and perinatal period was normal except patient has oligohydramnios and low birthweight baby and in case 2 she had oligohydramnios and large baby. Our cases add to the safely data of use of olanzapine in pregnancy, particularly in Indian settings. While conclusive elucidation still awaits more such reports from India and well-controlled studies.
患有精神分裂症的女性在孕期及产后症状加重或复发的风险很高。停用抗精神病药物时复发更为频繁。孕期持续使用抗精神病药物已很常见,奥氮平是常用的抗精神病药物。了解奥氮平在印度环境中的安全性非常重要。我们论文的目的是报告两例孕期使用奥氮平的病例,讨论其安全性概况以及对母亲和胎儿的不良影响。在我们的两个病例中,整个孕期都持续使用奥氮平,根据精神症状,患者临床保持稳定。病例1整个产前和围产期正常,只是患者羊水过少且婴儿出生体重低;病例2患者羊水过少且婴儿体型大。我们的病例增加了孕期使用奥氮平的安全性数据,特别是在印度环境中。虽然最终的阐明仍有待印度更多此类报告以及严格对照研究。